Phospho-MDC1 (S513) Antibody

What is MDC1 and what role does phosphorylation at Ser513 play in its function?

MDC1 (Mediator of DNA Damage Checkpoint 1) is a large nuclear protein (226 kDa) that plays a critical role in the DNA damage response (DDR). It contains an N-terminal forkhead-associated (FHA) domain, a PST-repeat region in the middle, and a tandem BRCT domain at the C-terminus . Phosphorylation at Ser513 is one of several post-translational modifications that regulate MDC1's interactions with other proteins in the DNA damage response pathway. Unlike the constitutive phosphorylation of the SDT motifs that mediate interactions with the MRN complex, Ser513 phosphorylation may be involved in different protein-protein interactions or regulatory mechanisms .

The sequence context of Ser513 (L-E-R-SP-Q) differs from the SDT motifs (Ser-Asp-Thr) that are phosphorylated by CK2 and mediate interactions with NBS1 . This suggests that Ser513 phosphorylation might have distinct regulatory functions in the DNA damage response pathway or cell cycle regulation.

How is the Phospho-MDC1 (Ser513) antibody produced and what are its key specifications?

The Phospho-MDC1 (Ser513) antibody is a rabbit polyclonal antibody produced by immunizing rabbits with a synthetic phosphopeptide derived from the human MDC1 protein around the phosphorylation site of Ser513 (L-E-R-SP-Q) . The antibody is then purified through affinity chromatography using the epitope-specific phosphopeptide . Non-phospho-specific antibodies are removed through chromatography using the non-phosphorylated peptide to ensure specificity.

Key specifications of the antibody include:

The antibody specifically detects endogenous levels of MDC1 only when phosphorylated at Ser513, making it a valuable tool for studying this particular post-translational modification .

What are the optimal protocols for using Phospho-MDC1 (Ser513) antibody in immunohistochemistry (IHC)?

For optimal immunohistochemistry results with Phospho-MDC1 (Ser513) antibody, follow these research-validated protocols:

• Sample preparation:

  • Fix tissue sections in 10% neutral buffered formalin (24 hours)

  • Process, embed in paraffin, and cut 4-6 μm sections

  • Mount sections on positively charged slides

• Antigen retrieval:

  • Deparaffinize and rehydrate sections through xylenes and graded ethanol series

  • Perform heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) for 20 minutes

  • Cool sections to room temperature (~20 minutes)

• Staining procedure:

  • Block endogenous peroxidase activity with 3% H₂O₂ in methanol (10 minutes)

  • Block non-specific binding with 5% normal goat serum in PBS (1 hour)

  • Apply primary antibody at 1:50-1:100 dilution in blocking buffer (overnight at 4°C)

  • Wash 3 times with PBS-T (5 minutes each)

  • Apply appropriate HRP-conjugated secondary antibody (1:200-1:500) for 1 hour at room temperature

  • Wash 3 times with PBS-T (5 minutes each)

  • Develop with DAB substrate until optimal signal-to-noise is achieved (2-10 minutes)

  • Counterstain with hematoxylin, dehydrate, and mount

• Controls and validation:

  • Include a positive control (human brain tissue is recommended)

  • Include a negative control (primary antibody omitted)

  • Consider including a phosphatase-treated control to confirm phospho-specificity

The optimal working dilution should be determined empirically for each experimental system, as background and signal strength can vary depending on tissue type and fixation conditions .

How can researchers validate the specificity of Phospho-MDC1 (Ser513) antibody for their experimental system?

Validating antibody specificity is crucial for ensuring reliable experimental results. For Phospho-MDC1 (Ser513) antibody, implement these verification strategies:

• Phosphatase treatment controls:

  • Split your sample into two aliquots

  • Treat one with lambda phosphatase before immunoblotting or immunostaining

  • Specific phospho-antibodies should show signal reduction/elimination after phosphatase treatment, as demonstrated for MDC1 S329/T331 phosphorylation

• Knockdown/knockout validation:

  • Perform siRNA-mediated knockdown or CRISPR-Cas9 knockout of MDC1

  • Compare antibody signal between control and MDC1-depleted samples

  • A specific antibody will show significantly reduced signal in depleted samples

• Peptide competition assay:

  • Pre-incubate the antibody with excess phosphorylated peptide (used as immunogen)

  • In parallel, pre-incubate with non-phosphorylated peptide

  • A specific phospho-antibody will be blocked by the phospho-peptide but not by the non-phospho-peptide

• Induction experiments:

  • If conditions altering Ser513 phosphorylation are known, compare antibody signal between baseline and induced conditions

  • For example, test during different cell cycle phases or after DNA damage if Ser513 phosphorylation is regulated by these conditions

• Mass spectrometry correlation:

  • If possible, validate antibody detection with mass spectrometry analysis of immunoprecipitated MDC1

  • Confirm the presence of phosphorylation at Ser513 in samples showing positive antibody signal

These validation strategies establish confidence in the antibody's specificity and ensure that observed signals truly represent MDC1 phosphorylated at Ser513 .

How does MDC1 phosphorylation coordinate the recruitment of DNA repair proteins to damage sites?

MDC1 serves as a molecular scaffold that organizes the hierarchical assembly of DNA damage response proteins through phosphorylation-dependent interactions. This coordination occurs through multiple mechanisms:

• γH2AX-MDC1 interaction:

  • DNA double-strand breaks (DSBs) activate ATM kinase, which phosphorylates histone H2AX (creating γH2AX)

  • MDC1 binds directly to γH2AX via its tandem BRCT domains with high specificity

  • This interaction requires the phosphorylated C-terminus of H2AX (pSQEY motif)

  • The crystal structure reveals that MDC1's BRCT domains are uniquely tailored for γH2AX recognition

• MDC1-MRN complex interaction:

  • MDC1 contains multiple SDT motifs (Ser-Asp-Thr) that are constitutively phosphorylated by casein kinase 2 (CK2)

  • These phosphorylated SDT motifs directly bind to the FHA domain of NBS1 (part of the MRN complex)

  • This interaction is critical for retention of MRN at DNA damage sites

  • Mutation of the NBS1 FHA domain (R28A) disrupts this interaction and abolishes MRN accumulation at DSBs

• MDC1-ATM interaction:

  • MDC1 directly binds to activated ATM (phosphorylated at Ser1981) via its FHA domain

  • This interaction creates a positive feedback loop that amplifies the DNA damage signal

  • ATM retention at DSBs requires both Ser1981 phosphorylation and MDC1

• MDC1 as a platform for ubiquitin signaling:

  • MDC1 is phosphorylated by ATM at TQXF clusters following DNA damage

  • These phosphorylated motifs recruit the E3 ubiquitin ligase RNF8

  • RNF8 initiates ubiquitination cascades that recruit 53BP1 and BRCA1

This multi-layered, phosphorylation-dependent coordination allows precise spatiotemporal control of the DNA damage response, ensuring that repair factors are recruited in the correct sequence and only to genuine sites of DNA damage .

What is the relationship between MDC1's different phosphorylation sites, including Ser513, and how do they collectively regulate DNA damage response?

MDC1 contains multiple phosphorylation sites that serve distinct functions in regulating the DNA damage response through different protein-protein interactions:

• Constitutive phosphorylation sites (including SDT motifs):

  • Six evolutionarily conserved SDT (Ser-Asp-Thr) motifs located between Ser218 and Asp455 in human MDC1

  • Constitutively phosphorylated by casein kinase 2 (CK2) on both Ser and Thr residues

  • Mediate interaction with the FHA domain of NBS1, recruiting the MRN complex to DSBs

  • Present in undamaged cells and not significantly changed after DNA damage

  • CK2 inhibition prevents MDC1-MRN interaction and disrupts MRN foci formation

• DNA damage-induced phosphorylation sites:

  • TQXF clusters phosphorylated by ATM following DNA damage

  • Serve as binding sites for the FHA domain of RNF8

  • Initiate ubiquitination cascades required for 53BP1 and BRCA1 recruitment

  • These sites show increased phosphorylation after ionizing radiation

• Ser513 phosphorylation:

  • Located in a sequence context (L-E-R-SP-Q) distinct from SDT motifs

  • Not part of the characterized SDT repeats that bind NBS1

  • May have an independent function in regulating MDC1 activity

  • Specific kinase responsible and regulation pattern not fully characterized in the provided search results

• Other phosphorylation sites:

  • Large-scale phosphoproteomic studies have identified numerous additional phosphorylation sites in MDC1

  • These sites are distributed throughout the protein and may have regulatory roles yet to be characterized

The functional interplay between these different phosphorylation events creates a complex regulatory network. For example, the constitutive SDT phosphorylation enables immediate MDC1-MRN complex binding at DSBs, while damage-induced phosphorylation acts as a second layer of regulation to orchestrate subsequent steps in the repair process. Ser513 phosphorylation likely contributes to this regulatory network, potentially influencing MDC1's interactions with yet unidentified partners or regulating its other functions in the DNA damage response .

How can researchers investigate the temporal dynamics of MDC1 Ser513 phosphorylation during the DNA damage response?

Investigating the temporal dynamics of MDC1 Ser513 phosphorylation requires sophisticated experimental approaches that combine high temporal resolution with specificity. Researchers can implement the following methodologies:

• Time-course analysis with synchronized cells:

  • Synchronize cells using techniques like double thymidine block or nocodazole treatment

  • Induce DNA damage at specific cell cycle phases (G1, S, G2/M)

  • Collect samples at defined time points (30 seconds to 24 hours post-damage)

  • Analyze Ser513 phosphorylation by western blotting and immunofluorescence

  • Compare with other phosphorylation events (γH2AX formation, ATM activation)

• Live-cell imaging approaches:

  • Generate cell lines expressing fluorescently-tagged MDC1

  • Use the Phospho-MDC1 (Ser513) antibody for immunofluorescence at fixed timepoints

  • Alternatively, develop a phospho-specific biosensor for Ser513

  • Perform laser micro-irradiation to induce localized DNA damage

  • Track recruitment kinetics using spinning disk confocal microscopy

  • Compare with known MDC1 dynamics (note: S329/T331 phosphorylation was detected both before and after DNA damage)

• Quantitative mass spectrometry:

  • Implement SILAC (Stable Isotope Labeling with Amino acids in Cell culture) approach

  • Induce DNA damage and collect samples at multiple timepoints

  • Immunoprecipitate MDC1 and perform phospho-peptide enrichment

  • Analyze by LC-MS/MS to quantify Ser513 phosphorylation relative to other sites

  • Create temporal profiles of multiple phosphorylation events

• Phosphatase inhibition experiments:

  • Treat cells with phosphatase inhibitors at different timepoints after DNA damage

  • Determine if Ser513 phosphorylation is dynamically regulated by phosphatases

  • Compare stability of Ser513 phosphorylation with constitutive SDT phosphorylation

  • Assess if Ser513 phosphorylation stabilizes MDC1 (note: S329/T331 phosphorylation was associated with more stable MDC1 after irradiation)

These approaches, particularly when used in combination, can reveal whether Ser513 phosphorylation is constitutive (like the SDT motifs) or damage-induced, and how it correlates temporally with other steps in the DNA damage response pathway .

What strategies can be employed to identify proteins that specifically interact with MDC1 when phosphorylated at Ser513?

To identify proteins that specifically interact with phosphorylated Ser513 of MDC1, researchers should implement these advanced interactome approaches:

• Phospho-peptide pull-down coupled with mass spectrometry:

  • Synthesize Ser513-phosphorylated and non-phosphorylated peptides (similar to the SDTD approach in result )

  • Couple peptides to beads and incubate with nuclear extracts

  • Elute bound proteins and identify by mass spectrometry

  • Compare proteins that bind specifically to the phosphorylated form

  • Validate with reciprocal co-immunoprecipitation experiments

• BioID or TurboID proximity labeling:

  • Generate constructs expressing MDC1 wild-type, S513A (phospho-deficient), and S513E (phospho-mimetic) fused to BioID/TurboID

  • Express in cells and activate biotin labeling

  • Purify biotinylated proteins and identify by mass spectrometry

  • Compare interactomes between variants to identify phospho-specific interactions

  • This approach captures both stable and transient interactions

• CRISPR-Cas9 knock-in of endogenous tags:

  • Generate cell lines expressing MDC1 with an endogenous epitope tag

  • Perform immunoprecipitation followed by phospho-specific western blotting

  • Use Phospho-MDC1 (Ser513) antibody to confirm phosphorylation status

  • Identify co-precipitating proteins by mass spectrometry

  • Compare interactomes in different conditions (±DNA damage, ±kinase inhibitors)

• Crosslinking mass spectrometry (XL-MS):

  • Utilize protein crosslinking in living cells

  • Immunoprecipitate MDC1 using the Phospho-MDC1 (Ser513) antibody

  • Digest and analyze crosslinked peptides by mass spectrometry

  • Map interaction interfaces to determine structural details

  • This method provides information about interaction topology

• Protein domain arrays:

  • Screen libraries of protein domains (FHA, BRCT, etc.) against phosphorylated and non-phosphorylated Ser513 peptides

  • Identify domains that specifically recognize phosphorylated Ser513

  • Follow up with full-length protein interaction studies

  • This approach can identify the specific domains mediating interactions

These approaches have proven successful for identifying interaction partners of other phosphorylated residues in MDC1. For example, similar methods revealed that the MRN complex specifically interacts with phosphorylated SDT motifs via the NBS1 FHA domain .

What are common challenges when using Phospho-MDC1 (Ser513) antibody in experiments, and how can they be addressed?

Researchers working with Phospho-MDC1 (Ser513) antibody may encounter several technical challenges. Here are evidence-based solutions for addressing these issues:

• High background in immunostaining:

  • Cause: Insufficient blocking or non-specific antibody binding

  • Solution: Increase blocking time (2-3 hours), use 5% BSA instead of serum, add 0.1% Triton X-100 to antibody dilution buffer

  • Alternative approach: Try a more stringent washing protocol with higher salt concentration (up to 500mM NaCl in PBS)

• Weak or no signal in western blotting:

  • Cause: Low abundance of phosphorylated MDC1 or protein degradation

  • Solution: Enrich nuclear proteins before western blotting as MDC1 is nuclear

  • Alternative approach: Use phosphatase inhibitors during sample preparation (10mM NaF, 1mM Na₃VO₄, 20mM β-glycerophosphate)

  • Validation: Include positive control lysates from cells known to express phosphorylated MDC1

• Non-specific bands in western blotting:

  • Cause: Cross-reactivity with other phosphorylated proteins

  • Solution: Use more stringent washing conditions and optimize antibody dilution (start with 1:1000)

  • Validation: Include MDC1 knockout/knockdown controls to identify specific bands

  • Alternative approach: Pre-absorb antibody with non-specific proteins before use

• Variability between experiments:

  • Cause: Differences in phosphorylation levels due to cell culture conditions

  • Solution: Standardize cell culture conditions, particularly confluency and serum levels

  • Alternative approach: Always include internal controls and normalize signal to total MDC1 levels

  • Validation: Monitor phosphorylation of other sites (e.g., S329/T331) shown to be constitutive

• Loss of signal during sample processing:

  • Cause: Phosphatase activity during sample preparation

  • Solution: Prepare samples on ice, use phosphatase inhibitor cocktails, minimize processing time

  • Alternative approach: Use hot lysis buffer (1% SDS, 10mM Tris pH 7.4, boiled) to rapidly inactivate phosphatases

• Difficulty detecting endogenous protein:

  • Cause: Low abundance of endogenous phosphorylated MDC1

  • Solution: Use immunoprecipitation to concentrate MDC1 before detection

  • Alternative approach: Treat cells with phosphatase inhibitors to increase phosphorylation levels

  • Validation: Try detecting after DNA damage, which may alter protein levels or localization

Understanding these challenges and implementing appropriate strategies will significantly improve experimental outcomes when working with Phospho-MDC1 (Ser513) antibody .

How do researchers interpret contradictory results when studying MDC1 phosphorylation in different experimental systems or conditions?

Interpreting contradictory results about MDC1 phosphorylation requires careful analysis of experimental conditions and biological context. Follow this methodological framework to resolve discrepancies:

• Analyze cell type-specific differences:

  • Different cell lines may exhibit varying levels of kinases and phosphatases

  • Compare expression levels of relevant kinases (CK2, ATM) and phosphatases across cell types

  • Examine cell cycle distribution, as phosphorylation status may vary by cell cycle phase

  • Consider tissue-specific functions of MDC1 that might influence its regulation

• Evaluate experimental conditions systematically:

  • Create a detailed comparison table of contradictory studies, including:

    • Cell synchronization methods

    • DNA damage induction approach (IR dose, chemical agents, etc.)

    • Sample collection timing

    • Lysis conditions and phosphatase inhibitors used

    • Detection methods (antibodies, mass spectrometry)

  • Standardize conditions across experiments to determine if discrepancies persist

• Assess antibody-related factors:

  • Different phospho-specific antibodies may have varying sensitivities and specificities

  • Perform side-by-side comparisons using multiple antibody clones

  • Validate each antibody independently using the methods described in FAQ 4.2

  • Consider epitope accessibility in different experimental contexts

• Investigate context-dependent regulation:

  • MDC1 functions in multiple processes beyond canonical DNA damage response

  • Test whether contradictory results correlate with specific cellular stresses

  • Examine if other post-translational modifications influence Ser513 phosphorylation

  • Consider cross-talk between different phosphorylation sites (e.g., SDT motifs vs. Ser513)

• Reconciliation strategies for contradictory data:

  • Perform time-course experiments with high temporal resolution

  • Use phosphatase treatment controls to verify phospho-specificity

  • Implement genetic approaches (phospho-mimetic/phospho-deficient mutants)

  • Consider alternative methods like Phos-tag gels to detect mobility shifts

  • Utilize advanced techniques like targeted mass spectrometry for absolute quantification

Case example: Research has shown that while some MDC1 phosphorylation sites (SDT motifs) are constitutively phosphorylated by CK2, others are induced by DNA damage through ATM. Additionally, phosphorylation at S329/T331 was detected in both undamaged and irradiated cells, but appeared to stabilize MDC1 after damage . Such nuanced regulation could explain contradictory observations if experimental systems differentially capture these distinct aspects of MDC1 phosphorylation dynamics .

What emerging technologies and approaches could advance our understanding of MDC1 Ser513 phosphorylation in DNA damage response?

Several cutting-edge technologies hold promise for deepening our understanding of MDC1 Ser513 phosphorylation:

• Single-cell phosphoproteomics:

  • Enables measurement of phosphorylation heterogeneity within cell populations

  • Can reveal cell cycle-dependent regulation of Ser513 phosphorylation

  • Allows correlation with other signaling events at the single-cell level

  • Recently demonstrated feasibility for studying ~1000 phosphosites across thousands of cells

• CRISPR-based phosphorylation site editing:

  • Generate precise S513A and S513E knock-in mutations in endogenous MDC1

  • Evaluate phenotypic consequences on DNA damage response kinetics

  • Combine with multi-omics approaches to assess global impacts

  • Compare with known phenotypes of other MDC1 phospho-mutants (e.g., SDT motifs)

• Super-resolution microscopy coupled with phospho-specific detection:

  • Apply techniques like STORM, PALM, or expansion microscopy

  • Visualize nanoscale organization of phosphorylated MDC1 at damage sites

  • Determine colocalization with other repair factors at 10-20 nm resolution

  • Track temporal changes in spatial organization during repair

• Cryo-electron microscopy of phosphorylation-dependent complexes:

  • Determine structures of protein complexes containing phosphorylated MDC1

  • Reveal how Ser513 phosphorylation induces conformational changes

  • Compare with structures involving other phosphorylated regions (e.g., SDT motifs)

  • Provide atomic-level insight into phosphorylation-dependent interactions

• Optogenetic control of phosphorylation:

  • Develop light-inducible kinase systems targeting MDC1 Ser513

  • Enable precise temporal control of phosphorylation independent of DNA damage

  • Determine sufficiency of Ser513 phosphorylation for specific interactions

  • Assess functional consequences in living cells with high temporal resolution

• Integrative multi-omics approaches:

  • Combine phosphoproteomics, interactomics, and functional genomics

  • Generate comprehensive models of MDC1 phosphorylation networks

  • Identify connections between Ser513 and other regulatory modifications

  • Predict functional impacts using machine learning approaches

These emerging technologies could help resolve whether Ser513 phosphorylation represents a constitutive modification (like the SDT motifs) or a damage-induced event, identify its specific binding partners, and determine its precise role in the hierarchical assembly of repair factors at DNA damage sites .

What are the potential clinical and translational implications of research on MDC1 phosphorylation and DNA damage response pathways?

Research on MDC1 phosphorylation, including at Ser513, has significant translational potential in multiple clinical domains:

• Cancer diagnostics and prognostics:

  • Phosphorylated MDC1 could serve as a biomarker for DNA damage response defects

  • Immunohistochemistry using phospho-specific antibodies might stratify tumors

  • Different phosphorylation patterns could indicate specific repair deficiencies

  • Potential applications include:

    • Predicting therapy response

    • Identifying candidates for specific targeted therapies

    • Monitoring treatment efficacy

    • Early detection of recurrence

• Targeted cancer therapies:

  • Inhibiting specific phosphorylation-dependent interactions of MDC1

  • Synthetic lethality approaches targeting tumors with specific repair defects

  • Development of proteolysis-targeting chimeras (PROTACs) against phosphorylated MDC1

  • Potential therapeutic strategies include:

    • Blocking MDC1-NBS1 interactions to sensitize cancer cells to radiotherapy

    • Targeting kinases responsible for MDC1 phosphorylation (e.g., CK2 inhibitors)

    • Disrupting MDC1-γH2AX binding in combination with PARP inhibitors

• Aging and neurodegeneration:

  • MDC1 phosphorylation status may change during aging and in neurodegenerative diseases

  • DNA damage accumulation is a hallmark of aging and neurodegeneration

  • Understanding MDC1 regulation could provide insights into age-related DNA repair defects

  • Potential applications include:

    • Biomarkers for neurodegeneration

    • Interventions to enhance DNA repair in aging tissues

    • Neuroprotective strategies targeting MDC1 pathways

• Radiation protection and biodosimetry:

  • Phosphorylated MDC1 levels could indicate radiation exposure severity

  • Development of point-of-care tests for radiation biodosimetry

  • Screening compounds that modulate MDC1 phosphorylation for radioprotection

  • Applications in:

    • Radiation oncology

    • Nuclear accident response

    • Space medicine

• Personalized medicine approaches:

  • Genetic variations affecting MDC1 phosphorylation sites

  • Pharmacogenomic strategies based on MDC1 pathway status

  • Tailoring cancer therapies based on DNA damage response profiling

  • Clinical decision support tools incorporating MDC1 phosphorylation status